Question 1

What is Belite Bio?

Accepted Answer

Belite Bio is a Company.

Question 2

How often does Belite Bio appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 15 articles.

Question 3

When was Belite Bio first tracked by Ergen?

Accepted Answer

First tracked on Jun 02, 2026.

Question 4

When was Belite Bio last mentioned in news?

Accepted Answer

Last active on Jun 13, 2026.

Question 5

What is Belite Bio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 42 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Belite Bio in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Belite Bio?

Accepted Answer

Belite_Bio to attend Goldman Sachs conference (Jun 02, 2026, 6 articles).

Question 8

How did the "Belite_Bio to attend Goldman Sachs conference" event impact Belite Bio?

Accepted Answer

Belite Bio will participate in the Goldman Sachs 47th Annual Global Healthcare Conference, providing an opportunity to present its clinical-stage drug development and potentially attract investor interest.

Question 9

How did the "Belite_Bio Submits Tinlarebant NDA" event impact Belite Bio?

Accepted Answer

Belite Bio completed the rolling submission of its New Drug Application for tinlarebant to the United States — Food and Drug Administration for the treatment of Stargardt disease type 1. This is a significant milestone for the company, potentially leading to the first approved treatment for this rare disease.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.